136 related articles for article (PubMed ID: 26378038)
1. Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells.
Borbely G; Haldosen LA; Dahlman-Wright K; Zhao C
Oncotarget; 2015 Oct; 6(32):33623-35. PubMed ID: 26378038
[TBL] [Abstract][Full Text] [Related]
2. Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.
Ceribelli M; Kelly PN; Shaffer AL; Wright GW; Xiao W; Yang Y; Mathews Griner LA; Guha R; Shinn P; Keller JM; Liu D; Patel PR; Ferrer M; Joshi S; Nerle S; Sandy P; Normant E; Thomas CJ; Staudt LM
Proc Natl Acad Sci U S A; 2014 Aug; 111(31):11365-70. PubMed ID: 25049379
[TBL] [Abstract][Full Text] [Related]
3. Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors.
Nieto-Jiménez C; Alcaraz-Sanabria A; Pérez-Peña J; Corrales-Sánchez V; Serrano-Heras G; Galán-Moya EM; Serrano-Oviedo L; Montero JC; Burgos M; Llopis J; Pandiella A; Ocaña A
Oncotarget; 2017 Mar; 8(12):19478-19490. PubMed ID: 28061448
[TBL] [Abstract][Full Text] [Related]
4. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses.
Belkina AC; Nikolajczyk BS; Denis GV
J Immunol; 2013 Apr; 190(7):3670-8. PubMed ID: 23420887
[TBL] [Abstract][Full Text] [Related]
5. Altered regulation and expression of genes by BET family of proteins in COPD patients.
Malhotra R; Kurian N; Zhou XH; Jiang F; Monkley S; DeMicco A; Clausen IG; Dellgren G; Edenro G; Ahdesmäki MJ; Clausen M; Öberg L; Israelsson E; Belfield G; Vaarala O
PLoS One; 2017; 12(3):e0173115. PubMed ID: 28248992
[TBL] [Abstract][Full Text] [Related]
6. BETs abet Tam-R in ER-positive breast cancer.
Alluri PG; Asangani IA; Chinnaiyan AM
Cell Res; 2014 Aug; 24(8):899-900. PubMed ID: 25001387
[TBL] [Abstract][Full Text] [Related]
7. Mocetinostat as a novel selective histone deacetylase (HDAC) inhibitor in the promotion of apoptosis in glioblastoma cell line C6 and T98G.
Khathayer F; Mikael M
Res Sq; 2024 Apr; ():. PubMed ID: 38645087
[TBL] [Abstract][Full Text] [Related]
8. BET inhibition induces vulnerability to MCL1 targeting through upregulation of fatty acid synthesis pathway in breast cancer.
Yan G; Luna A; Wang H; Bozorgui B; Li X; Sanchez M; Dereli Z; Kahraman N; Kara G; Chen X; Zheng C; McGrail D; Sahni N; Lu Y; Babur O; Cokol M; Lim B; Ozpolat B; Sander C; Mills GB; Korkut A
Cell Rep; 2022 Sep; 40(11):111304. PubMed ID: 36103824
[TBL] [Abstract][Full Text] [Related]
9. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.
Mazur PK; Herner A; Mello SS; Wirth M; Hausmann S; Sánchez-Rivera FJ; Lofgren SM; Kuschma T; Hahn SA; Vangala D; Trajkovic-Arsic M; Gupta A; Heid I; Noël PB; Braren R; Erkan M; Kleeff J; Sipos B; Sayles LC; Heikenwalder M; Heßmann E; Ellenrieder V; Esposito I; Jacks T; Bradner JE; Khatri P; Sweet-Cordero EA; Attardi LD; Schmid RM; Schneider G; Sage J; Siveke JT
Nat Med; 2015 Oct; 21(10):1163-71. PubMed ID: 26390243
[TBL] [Abstract][Full Text] [Related]
10. BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.
Ambrosini G; Sawle AD; Musi E; Schwartz GK
Oncotarget; 2015 Oct; 6(32):33397-409. PubMed ID: 26397223
[TBL] [Abstract][Full Text] [Related]
11. Development of novel cellular histone-binding and chromatin-displacement assays for bromodomain drug discovery.
Zhan Y; Kost-Alimova M; Shi X; Leo E; Bardenhagen JP; Shepard HE; Appikonda S; Vangamudi B; Zhao S; Tieu TN; Jiang S; Heffernan TP; Marszalek JR; Toniatti C; Draetta G; Tyler J; Barton M; Jones P; Palmer WS; Geck Do MK; Andersen JN
Epigenetics Chromatin; 2015; 8():37. PubMed ID: 26396593
[TBL] [Abstract][Full Text] [Related]
12. BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.
Zhu H; Bengsch F; Svoronos N; Rutkowski MR; Bitler BG; Allegrezza MJ; Yokoyama Y; Kossenkov AV; Bradner JE; Conejo-Garcia JR; Zhang R
Cell Rep; 2016 Sep; 16(11):2829-2837. PubMed ID: 27626654
[TBL] [Abstract][Full Text] [Related]
13. Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial.
Nicholls SJ; Puri R; Wolski K; Ballantyne CM; Barter PJ; Brewer HB; Kastelein JJ; Hu B; Uno K; Kataoka Y; Herrman JP; Merkely B; Borgman M; Nissen SE
Am J Cardiovasc Drugs; 2016 Feb; 16(1):55-65. PubMed ID: 26385396
[TBL] [Abstract][Full Text] [Related]
14. The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition.
Yao W; Yue P; Khuri FR; Sun SY
Oncotarget; 2015 Oct; 6(33):34669-79. PubMed ID: 26415225
[TBL] [Abstract][Full Text] [Related]
15. Autism-like syndrome is induced by pharmacological suppression of BET proteins in young mice.
Sullivan JM; Badimon A; Schaefer U; Ayata P; Gray J; Chung CW; von Schimmelmann M; Zhang F; Garton N; Smithers N; Lewis H; Tarakhovsky A; Prinjha RK; Schaefer A
J Exp Med; 2015 Oct; 212(11):1771-81. PubMed ID: 26392221
[TBL] [Abstract][Full Text] [Related]
16. The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.
Ma Y; Wang L; Neitzel LR; Loganathan SN; Tang N; Qin L; Crispi EE; Guo Y; Knapp S; Beauchamp RD; Lee E; Wang J
Clin Cancer Res; 2017 Apr; 23(8):2027-2037. PubMed ID: 27678457
[No Abstract] [Full Text] [Related]
17. BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling.
Andrieu G; Tran AH; Strissel KJ; Denis GV
Cancer Res; 2016 Nov; 76(22):6555-6567. PubMed ID: 27651315
[TBL] [Abstract][Full Text] [Related]
18. Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.
Sahni JM; Gayle SS; Bonk KL; Vite LC; Yori JL; Webb B; Ramos EK; Seachrist DD; Landis MD; Chang JC; Bradner JE; Keri RA
J Biol Chem; 2016 Nov; 291(45):23756-23768. PubMed ID: 27650498
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Super-Enhancer Activity in Autoinflammatory Site-Derived T Cells Reduces Disease-Associated Gene Expression.
Peeters JG; Vervoort SJ; Tan SC; Mijnheer G; de Roock S; Vastert SJ; Nieuwenhuis EE; van Wijk F; Prakken BJ; Creyghton MP; Coffer PJ; Mokry M; van Loosdregt J
Cell Rep; 2015 Sep; 12(12):1986-96. PubMed ID: 26387944
[TBL] [Abstract][Full Text] [Related]
20. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Shu S; Lin CY; He HH; Witwicki RM; Tabassum DP; Roberts JM; Janiszewska M; Huh SJ; Liang Y; Ryan J; Doherty E; Mohammed H; Guo H; Stover DG; Ekram MB; Brown J; D'Santos C; Krop IE; Dillon D; McKeown M; Ott C; Qi J; Ni M; Rao PK; Duarte M; Wu SY; Chiang CM; Anders L; Young RA; Winer E; Letai A; Barry WT; Carroll JS; Long H; Brown M; Liu XS; Meyer CA; Bradner JE; Polyak K
Nature; 2016 Jan; 529(7586):413-417. PubMed ID: 26735014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
